Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment
Morning nivolumab administration may be associated with improved OS in patients with NSCLC. Prospective studies are warranted to clarify the clinical relevance of infusion timing and its possible contribution to treatment outcomes.
Authors
- Kyoichi Okishio (ORCID: https://orcid.org/0000-0002-6348-1302)
- Yuji Inagaki (ORCID: https://orcid.org/0000-0002-2208-9478)
- Yoshihiko Taniguchi (ORCID: https://orcid.org/0000-0001-6387-3683)
- Akihiro Tamiya (ORCID: https://orcid.org/0000-0003-3599-2583)
- Motohiro Tamiya (ORCID: https://orcid.org/0000-0001-6529-3092)
- Akihiro Tsukaguchi (ORCID: https://orcid.org/0009-0009-6296-4386)
- Tsunehiro Tanaka (ORCID: https://orcid.org/0000-0001-6351-2992)
- Yuki Iwahashi
Institutions
- Osaka International Cancer Institute (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.21873/anticanres.17848
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00